行情

DBVT

DBVT

DBV Tech
NASDAQ

实时行情|Nasdaq Last Sale

5.01
-0.06
-1.18%
交易中 14:27 09/21 EDT
开盘
5.03
昨收
5.07
最高
5.07
最低
4.990
成交量
2.41万
成交额
--
52周最高
7.38
52周最低
1.350
市值
5.51亿
市盈率(TTM)
-4.2165
分时
5日
1月
3月
1年
5年
欧洲 ADR 周一上涨 1%,因能源巨头上涨,制药公司撤退
MT Newswires · 09/13 11:22
截至2021年8月31日公司表决权总数及股份总数月度情况
Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 00...
GlobeNewswire · 09/08 20:00
DBV Technologies 将参加即将举行的投资者会议
Montrouge, France, August 31, 2021 DBV Technologies to Participate at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that DBV Tech...
GlobeNewswire · 08/31 05:30
Beyond Air® 宣布首席财务官换届
GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, i...
GlobeNewswire · 08/20 20:15
Beyond Air 任命新首席财务官
MT Newswires · 08/20 16:31
截至2021年7月31日公司表决权总数及股份总数月度情况
Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010...
GlobeNewswire · 08/09 20:30
与 ODDO BHF 签订的 DBV Technologies 流动性合同半年报告
AMF REGULATED INFORMATIONMontrouge, France, August 6, 2021 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa...
GlobeNewswire · 08/06 20:30
欧洲 ADR 在周二交易中走高
MT Newswires · 08/03 11:52
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解DBVT最新的财务预测,通过DBVT每股收益,每股净资产,每股现金流等数据分析DBV Tech近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测DBVT价格均价为10.92,最高价位13.89,最低价为7.94。
EPS
机构持股
总机构数: 96
机构持股: 3,951.68万
持股比例: 35.92%
总股本: 1.10亿
类型机构数股数
增持
11
3.47万
建仓
5
7,357
减持
12
48.52万
平仓
2
2.07万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+0.34%
制药与医学研究
+0.75%
高管信息
Chairman/Chief Executive Officer/Director
Pierre-Henri Benhamou
Chief Operating Officer
David Schilansky
Executive Vice President/General Counsel
Joan Schmidt
Chief Scientific Officer
Hugh Sampson
Vice President - Research & Development
Lucie Mondoulet
Vice President - Business Development
Nathalie Donne
Director of Marketing
Veronique Foutel
Other
Wence Agbotounou
Other
Bertrand Dupont
Other
Pascale Ehouarn
Other
Laurent Martin
Director
Michel de Rosen
Director
Mailys Ferrere
Director
George Horner
Director
Didier Hoch
Director
Chahra Louafi
Director
Rafaele Tordjman
暂无数据
DBVT 简况
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

微牛提供DBV Technologies SA(NASDAQ-DBVT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的DBVT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易DBVT股票基本功能。